Four quick questions. One recommendation.
By treatment area
Formulated to work with light — not just alongside it. Young Goose collab. EWG Green. Made in USA.
About the research on this page. The studies cited here investigate photobiomodulation (PBM) as a therapeutic modality and the specific wavelengths used in PBM research — not Mito Red Light devices. The wavelengths in our panels were chosen because the peer-reviewed PBM literature supports them. Evidence levels and study counts reflect the broader research base, not studies of our products. See the full methodology note at the bottom of this page.
Photobiomodulation (PBM) exerts measurable effects on the vascular system through multiple mechanisms centered on endothelial nitric oxide (NO) production and mitochondrial function in vascular smooth muscle cells. Red (620–680 nm) and near-infrared (780–850 nm) wavelengths absorbed by vascular chromophores trigger endothelial NO synthase (eNOS) activation, leading to vasodilation, reduced peripheral resistance, and improved microvascular perfusion. These effects are relevant to a broad range of cardiovascular conditions including hypertension, peripheral artery disease, microcirculatory disorders, and endothelial dysfunction associated with diabetes and metabolic syndrome.
Human clinical evidence for PBM in cardiovascular contexts is growing but less mature than for musculoskeletal applications. Several RCTs and pilot studies document measurable improvements in blood flow velocity (via Doppler ultrasonography), microvascular density, endothelial function scores (flow-mediated dilation), and blood pressure parameters following repeated PBM. Intravascular laser irradiation of blood (ILIB) — a technique used clinically in some countries — applies low-power laser directly to blood via intravenous fiber optic, producing systemic photobiomodulation effects including reductions in LDL oxidation, platelet aggregation, and blood viscosity. Non-invasive transcutaneous PBM over major vessels shows related but attenuated effects.
Preclinical evidence is particularly strong for PBM in myocardial protection: rodent and large animal models of myocardial infarction show significantly reduced infarct size, preserved ejection fraction, and reduced cardiomyocyte apoptosis when PBM is applied before or after ischemia-reperfusion injury. Human cardiac applications are still experimental, but the mechanistic rationale — protecting mitochondria-rich cardiomyocytes from oxidative stress — is well-grounded. This category represents an emerging frontier where the biological plausibility significantly exceeds current clinical trial coverage.
PBM's vascular effects are primarily mediated through nitric oxide (NO) pathways. Red and near-infrared photons absorbed by oxyhemoglobin and cytochrome c oxidase in endothelial cells increase eNOS activity, releasing NO into surrounding vascular smooth muscle. NO activates guanylyl cyclase, raising cGMP and causing smooth muscle relaxation — the fundamental mechanism of vasodilation. PBM also reduces oxidative modification of LDL, attenuates platelet aggregation, and improves erythrocyte deformability for improved microvascular flow.
Studies in this category commonly demonstrate:
A curated selection from 300++ indexed studies.
Eight sessions of transcutaneous PBM at 660 nm over the radial artery produced significant reductions in systolic (−8 mmHg) and diastolic (−4 mmHg) blood pressure vs. sham, maintained at 4-week follow-up. Endothelin-1 (vasoconstrictor) significantly reduced in treatment group.
View on PubMed →Near-infrared PBM over the brachial artery significantly improved flow-mediated dilation (FMD: +3.2% vs. −0.4% sham) — a validated measure of endothelial function. ICAM-1 and VCAM-1 (endothelial inflammation markers) were also significantly reduced.
View on PubMed →Pre-ischemic PBM at 808 nm reduced infarct size by 47% vs. control and preserved left ventricular function at 24h. Mechanism: reduced cytochrome c release, preserved mitochondrial membrane potential, increased Bcl-2/Bax ratio in cardiomyocytes.
View on PubMed →ILIB (intravascular laser) produced significant reductions in oxidized LDL (−24%), platelet aggregation (−18%), and fibrinogen vs. sham over 10 sessions. Total cholesterol and triglycerides also modestly reduced. Demonstrated systemic cardiovascular effects via direct blood irradiation.
View on PubMed →Doppler ultrasonography confirmed significantly improved peak blood flow velocity and microvascular perfusion in diabetic foot with 830 nm PBM vs. control. TcPO2 (transcutaneous oxygen pressure) also improved, indicating better tissue oxygenation.
View on PubMed →Review found consistent evidence for improved microvascular perfusion, wound healing, and functional outcomes in PAD patients receiving PBM. Effect strongest in diabetic subgroup. Identified need for larger RCTs; safety across all studies was excellent.
View on PubMed →Based on analysis of 300++ peer-reviewed studies:
| Parameter | Typical Range | Notes |
|---|---|---|
| Wavelength | 630–660 nm (endothelial NO); 810–830 nm (deep vascular/cardiac) | Red for superficial vessels and endothelial effects; NIR for deeper vasculature and cardiac tissue (preclinical). |
| Dose (fluence) | 4–10 J/cm² | Higher doses used for transcutaneous application over major vessels. Direct endothelial effects at 4–6 J/cm². |
| Application site | Radial artery, brachial artery, femoral, or affected region | Transcutaneous over major arteries activates systemic NO release. Local application over affected vascular bed for peripheral conditions. |
| Session frequency | 3–5× per week | Most cardiovascular RCTs: 3–5 sessions/week for 4–8 weeks. Blood pressure effects: 8 sessions over 4 weeks sufficient in pilot RCTs. |
| Evidence maturity | Phase I–II (human); strong preclinical | Cardiovascular PBM is earlier in clinical development than musculoskeletal. Mechanistic rationale strong; larger RCTs needed. |
| Safety considerations | No adverse events in published trials | Caution with anti-coagulation therapy and PBM effects on platelet aggregation. Theoretical concern re: cardiac arrhythmias — not supported by published data. |
Clinical studies using Doppler ultrasonography and laser speckle imaging confirm that PBM increases blood flow velocity, microvascular perfusion, and tissue oxygenation in treated areas. The primary mechanism is eNOS activation → NO release → vasodilation. Effects have been documented in healthy subjects, diabetic patients, and those with peripheral vascular disease. Both local and systemic circulatory responses have been measured following transcutaneous PBM over major arteries.
Small RCTs have documented statistically significant reductions in systolic and diastolic blood pressure following transcutaneous PBM in hypertensive patients (approximately −8/−4 mmHg). Mechanisms include NO-mediated vasodilation and reduction of circulating endothelin-1 (a potent vasoconstrictor). While these effects are modest and unlikely to replace antihypertensive medications, they may be clinically meaningful as adjunct therapy. Larger confirmatory trials are needed before clinical recommendations can be made.
Compelling preclinical evidence shows PBM can protect cardiomyocytes from ischemia-reperfusion injury, reducing infarct size by 30–50% in animal models. Human cardiac applications are experimental — no published human cardiac PBM trials exist for acute MI. Indirect cardiovascular benefits (reduced blood pressure, improved endothelial function, reduced LDL oxidation) have been demonstrated in human pilots. This area represents a significant scientific frontier with strong mechanistic rationale awaiting clinical translation.
PBM activates endothelial nitric oxide synthase (eNOS) through photon absorption by hemoglobin and cytochrome c oxidase in endothelial cells. The resulting NO diffuses into vascular smooth muscle, activating guanylyl cyclase and raising cGMP — the classic vasodilatory signaling cascade. This is the same pathway activated by nitroglycerin but through photochemical rather than chemical means. NO from PBM also inhibits platelet aggregation and reduces endothelial expression of inflammatory adhesion molecules.
Multiple studies specifically in diabetic populations show PBM improves microvascular perfusion parameters (Doppler flow, TcPO2) and endothelial function (FMD). This is clinically relevant because diabetic microvascular disease is a major contributor to foot ulcers, neuropathy, and wound healing impairment. Near-infrared at 810–830 nm is preferred for diabetic vascular applications due to its deeper penetration and ability to reach compromised deep vascular beds.
ILIB is a technique used clinically in Russia, China, and some European countries that delivers low-power laser light (typically 630 nm, 1–3 mW) directly into the bloodstream via a fine fiber optic inserted into the antecubital vein. This irradiates blood cells and plasma directly, producing systemic PBM effects including reduced LDL oxidation, improved erythrocyte deformability, reduced platelet aggregation, and modest lipid-lowering effects. It is a medical procedure not equivalent to consumer LED panel application.
All — studies in this category from the PBM research database.
Search all 10,068+ studies across all categories: Open the Full Evidence Explorer →
The published research indexed and referenced on this page studies photobiomodulation (PBM) as a therapeutic modality and the specific wavelengths used in those studies — not Mito Red Light devices specifically. The wavelengths used across our panels were chosen because the peer-reviewed PBM literature supports them: this is where published evidence is deepest, where dosing parameters have been characterized in human studies, and where clinical guidelines (such as WALT for inflammation and pain) exist. Mito Red Light has not funded or conducted registered clinical trials on our specific devices, and the study counts referenced here reflect the broader PBM research base — not studies of our products.
Evidence levels follow GRADE methodology. Study counts reflect peer-reviewed photobiomodulation research drawn from major scientific literature databases, peer-reviewed journals, and other published research repositories. PBM response varies meaningfully by person, tissue, condition, dose, wavelength, and session timing; outcomes reported in the published literature may not be replicable for every user. Mito Red Light devices are not intended to diagnose, treat, cure, or prevent any disease. If you have a medical condition or are under a physician’s care, please consult your healthcare provider before beginning any photobiomodulation regimen.
